Wall Street analysts expect Isoray, Inc. (NYSE:ISR – Get Rating) to report earnings per share (EPS) of ($0.01) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Isoray’s earnings. The lowest EPS estimate is ($0.01) and the highest is $0.00. Isoray also reported earnings of ($0.01) per share in the same quarter last year. The firm is expected to report its next earnings results on Monday, January 1st.
On average, analysts expect that Isoray will report full year earnings of ($0.05) per share for the current financial year, with EPS estimates ranging from ($0.05) to ($0.04). For the next fiscal year, analysts forecast that the company will post earnings of ($0.02) per share, with EPS estimates ranging from ($0.05) to $0.02. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Isoray.
Separately, StockNews.com initiated coverage on Isoray in a report on Saturday. They issued a “sell” rating on the stock.
About Isoray (Get Rating)
Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.
- Get a free copy of the StockNews.com research report on Isoray (ISR)
- Short-Covering Begins In Big Lots
- Institutions Ring The Register On Toll Brothers Stock
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Indie Semiconductor Stock is Putting in a Bottom
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.